Skip to content

Evaluation of ABO Isoagglutinins Level in Blood Group O Donors

Evaluation of ABO Isoagglutinins Level in Blood Group O Donors

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04412993
Enrollment
100
Registered
2020-06-02
Start date
2021-10-31
Completion date
2022-10-31
Last updated
2021-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Isoagglutinins Level

Keywords

urgent blood transfusion , group O

Brief summary

Our study is aiming for evaluation f the titre of anti-A and anti-B in plasma of blood grop O donors, study the effect of pooling of blood product on the level of A and B isoagglutinins in blood group O donors and screening for the safest group o donors(who have the lowest anti-A antd anti-B titre) for transfusion in urgent need of blood.

Detailed description

the use of O blood group transfusion to patients of all groups has continued since the second world war, nevertheless the transfusion of group O plasma/ platelet concentrate to group A, B and AB recipient sometimes causes severe red cell destruction , Acute haemolysis has been reported following transfusion of non-iso group single donor platelet (PLT) concentrates and may be more common than is appreciated. This red blood cells destruction happens based on the fact that the sera from group O people contain two separable antibodies, anti-A and anti-B . When it comes to PLT transfusion therapy we are dealing with issues arising from the fact that PLTs contain both significant amounts of ABO antigen on their surface, as well as anti ABO isogglutinins in the donor's plasma which caused reduction the volume of incompatible plasma administrated. From another point of view the risk of high titer units is considered low with group O, post storage, pooled PLT concentrate. However its necessary to establish a (golden standard) method for the determination of antibody titer in order to be able to differentiate accurately the high titer donors. So, for improving the safety of group O plts we need to define a safe level of antibody titer or reduce the volume of incompatible plasma administrated.

Interventions

OTHERwithdraw blood samples

withdraw blood sample from gorup O donors

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults blood group O donors

Exclusion criteria

* Other blood groups donors. * Donors with history of chronic or autoimmune diseases

Design outcomes

Primary

MeasureTime frameDescription
Decrease the risk of red cell destruction resulting from transfusion of RBCs/ platelet concentrate group O transfusion in urgent cases.2 yearsUsing blood group typ O For other blood group types without causing any reaction resulting from blood transfusion .

Secondary

MeasureTime frameDescription
screening for the best group O donors to use for other groups urgent cases as a reserve for transfusion.2 yearsUsing blood group typ O For other blood group types without causing any reaction resulting from blood transfusion .

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026